Question 1

What side effects have been documented with Cerebrolysin?

Accepted Answer

The common ones are mild and short-lived, and they come up again and again in the trial reports. A 2010 review of the dementia trials names dizziness, or vertigo, as the most frequently reported adverse event. A 2012 safety review drawing on dementia and stroke trials lists vertigo, agitation and feeling hot as the most common events. The same review describes adverse reactions to Cerebrolysin as generally mild and transient. In a 53-patient Korean Alzheimer's trial, only one patient reported a febrile sensation, which was transient and mild. These are the effects common enough to be counted. A trial of a few hundred people will not catch something that happens once in thousands of infusions, which is why the case report further down this page matters.

Question 2

How safe is Cerebrolysin?

Accepted Answer

The fairest summary is that minor events happened about as often as on placebo, and the argument is about serious ones. Across three stroke trials pooled by Cochrane in 2017, 308 of 667 people given Cerebrolysin had an adverse event, against 307 of 668 given placebo. The 2013 Cochrane review of vascular dementia found that only non-serious adverse events were observed in the six trials it included. A 2024 network analysis of stroke medicines pointed the other way, placing cerebrolysin among the regimens with a higher rate of adverse effects than conventional care alone. Matching totals tell you the common, minor events ran at roughly the background rate seen in sick, elderly hospital patients. They do not settle the rarer and more serious events, and that is where the reviews part company.

Question 3

Did serious adverse events go up in the stroke trials?

Accepted Answer

This is the central safety dispute, and the answer depends on how the events are counted. The 2016 Cochrane review reported 62 of 589 people with serious adverse events on Cerebrolysin, against 46 of 600 on placebo. A 2017 revision found no significant difference in total serious events, but a rise in non-fatal ones, 20 of 667 against 8 of 668. The 2023 update kept that finding and noted that the increase was more prominent in trials giving 30 mL for 10 days. A 2021 safety meta-analysis of twelve trials and 2202 patients reached a different result, finding no statistically significant differences from placebo in any analysis. It even reported the lowest serious-event rate at the highest amount, 50 mL. These are largely different slices of overlapping trials rather than different data. A rise in non-fatal events can sit inside an unchanged total if fatal events move the other way, and Cochrane graded its own finding moderate rather than high certainty.

Question 4

Can Cerebrolysin cause a severe allergic reaction?

Accepted Answer

Yes, and one case is documented in detail. In a 2024 case report, an 85-year-old man recovering from a stroke developed a fulminant anaphylactic reaction, meaning sudden and severe, after an intravenous dose. The authors confirmed the reaction with laboratory tests, and the patient's vital functions were quickly restored under the hospital's standard protocol. They add that only rare cases of anaphylaxis due to cerebrolysin have been published to date. A case report shows that something can happen. It cannot say how often, and it is worth noting where this one happened: in a hospital, with the staff and drugs to manage it already in the room.

Question 5

How long can you take Cerebrolysin?

Accepted Answer

The studies did not test continuous use. Every long record behind this page is a series of separate courses, with months between them, and that distinction shapes how the question can be answered. The longest is a three-year Russian-language study in which 50 patients with early memory loss received an annual course of Cerebrolysin each year. Each yearly course was 20 intravenous infusions over 4 weeks, so three years meant 60 infusions spread across three years rather than three years of daily exposure. Across the vascular dementia trials pooled by Cochrane, follow-up ranged from 15 days to three years. A 2010 review of the dementia evidence called for longer term trials before its place in care could be settled. The three-year abstract reports how many participants progressed to dementia, but it gives no adverse-event figures. The longest exposure on record is therefore also one of the least documented for harm, and an undocumented record is not the same as a clean one. Continuous daily administration over months, as opposed to intermittent hospital courses, does not appear in any study behind this page.

Question 6

Is it risky after a brain bleed or a clot-busting drug?

Accepted Answer

This was tested on purpose, because a compound given after stroke has to be checked in patients who are bleeding or about to receive drugs that thin the blood. A 2010 placebo-controlled trial randomised 100 patients with haemorrhagic stroke, a bleed into the brain, to a 10-day course of 50 mL a day, and 96 of them completed it. In the CEREHETIS study, 126 patients got Cerebrolysin alongside the clot-busting drug alteplase and 215 got alteplase alone. Its authors concluded that adding Cerebrolysin early lowered the rate of symptomatic bleeding into the stroke in those patients, and they raised no safety concern. Read the design carefully. CEREHETIS was open-label, so everyone knew who received what, and bleeding was judged by people who knew. A lower bleeding rate in that setting is a signal rather than a settled result.

Question 7

What does Cerebrolysin interact with?

Accepted Answer

What exists are combinations that were tried in trials, not dedicated interaction studies. The 2012 safety review reports no problem seen when it was combined with the clot-busting drug alteplase, or with the dementia drugs donepezil and rivastigmine. In a 20-patient trial in motor neurone disease, it was given on top of riluzole, the standard medicine for that condition, and the combination was reported as tolerated. In a 398-patient Vietnamese stroke study, where it was given alone or with other nootropics, no drug-related adverse events were reported. In depressed rats, Cerebrolysin strengthened the effect of lithium, a mood-stabilising medicine. A combination that did not produce a reported problem is not the same as an interaction study, which would measure each drug with and without the other. None of the research behind this page did that.

Question 8

Is Cerebrolysin hard on the liver?

Accepted Answer

One paper raises a concern and reports a reassuring trend in the same breath. A 2022 study argues that concerns it could speed fatty liver disease toward cirrhosis, through a growth pathway it switches on, seem valid. Yet in stroke patients with damaged livers, Cerebrolysin improved AST levels, a blood marker of liver injury, in a majority of them. The 2012 safety review states that, to its authors' knowledge, it was not associated with major changes in vital signs or laboratory parameters. In rats given a bacterial toxin, it lessened liver damage in a dose-dependent way. The concern is a theoretical one drawn from biology, and the AST result comes from patients who were not randomised. Neither is a measured answer, which would need liver tests reported from a controlled trial.

Question 9

Does Cerebrolysin contain anything opioid-like?

Accepted Answer

A composition study says it does, which raises a fair question about mood and dependence. A 2019 Russian-language analysis found that it contains considerable amounts of Leu- and Met-enkephalins, the body's own opioid-like peptides. The same authors propose that these peptides stimulate the endorphin system, and they read this as a mood-stabilising effect. Agitation also appears among the common side effects listed above. Dependence, tolerance and withdrawal were not measured in any study behind this page, so the composition finding is a reason to ask the question rather than an answer to it.

Question 10

What happened when it was given to children?

Accepted Answer

Children are not absent from this literature, which is unusual for a compound in this category, and the populations involved were among the most vulnerable a trial can enrol. A randomised trial gave it to high-risk premature babies on top of a routine early intervention programme. A Russian-language study gave newborns with brain damage from poor blood flow around birth 10 injections every other day. A third gave 30 injections over two months to children aged 3 to 4 with developmental dysphasia, a severe speech and language disorder. None of these three abstracts reports adverse events, or states that there were none. That does not mean nothing happened. It means harm was not part of what the published summaries chose to describe, and the full papers would be the place to look before drawing any conclusion about children.

Question 11

Who was left out of the studies?

Accepted Answer

The trial rules shaped who the safety record describes, and they were often narrow. The Korean Alzheimer's trial took men and women admitted to hospitals with mild to moderate disease who were otherwise in good health. The ESCAS speech trial after stroke required right-handedness and Romanian as the mother tongue. The authors of a 2023 brain-injury trial listed the exclusion of specific patient populations among their own limitations. The CLINCH bleeding-stroke protocol notes that its restrictive eligibility criteria may limit how far its results apply. We could find no trial among these sources that enrolled healthy adults, pregnant women or people with serious liver or kidney disease. That does not mean harm is known for them; it means the record does not describe them.

Question 12

What has the FDA done about Cerebrolysin?

Accepted Answer

The FDA enforcement records we found hold two recalls of Cerebrolysin injections, both Class II and both about how the vials were made rather than about the peptides. In November 2020, 10 mL vials labelled CEREBROLYSIN, 107.5 MG/ML, for The Guyer Institute of Molecular Medicine in Indianapolis were recalled over production processes which cannot assure sterility. In July 2025, Cerebrolysin for Injection, all strengths and presentations, from GenoGenix, LLC in Boca Raton, Florida, was recalled for lack of assurance of sterility. A sterility failure in something infused into a vein is a real risk of its own. It belongs to the vial and its maker rather than to the compound, and it is a risk that none of the clinical trials above would ever have measured.

Question 13

Why do the safety reviews disagree?

Accepted Answer

Part of it is which trials go in, and part of it is who ran them. The 2020 Cochrane update notes that the manufacturer supported four multicentre stroke studies, by funding them or by supplying the infusions, placebo, codes, grants or statisticians. A 2017 meta-analysis warned that its own small number of trials might cause publication bias, where favourable results are more likely to be printed. The twelve-trial safety analysis and the Cochrane reviews also used different cut-offs for which trials qualified. That is ordinary in this kind of work, and it is why the same compound can look neutral in one pooled table and slightly worse than placebo in another. Neither review is the final answer on its own.

Cerebrolysin side effects and safety data